Second staining Subsequently, sections previously stained for S100, MAOB, and ABAT were incubated with guinea pig anti-GABA (1:100, Millipore ab175) and chicken anti-GFAP (1:200, Abcam ab4647) antibodies for 24 h
Study patients who achieved maximum tolerated dose of 10 mg or 15 mg tirzepatide weekly by week 36 were then randomized 1:1 to continue tirzepatide or receive matching placebo subq injections for 52 weeks
Unfortunately, high-dose NAC may not be readily available worldwide
Give yourself at least six months before making any judgments about whether this is working
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) A substudy of the phase 2 obesity trial specifically examined GLP3s effects on liver fat in participants with metabolic dysfunction-associated steatotic liver disease[12]: Mean relative liver fat reduction of 82.4% with 12 mg dose at 24 weeks 86% of participants on 12 mg achieved normal liver fat levels (below 5%) at 24 weeks Liver fat reductions significantly correlated with improvements in insulin sensitivity, abdominal fat, and metabolic parameters Dose-dependent improvements observed across all dose groups compared to placebo These results suggest potential therapeutic applications beyond weight management, addressing hepatic complications of obesity and metabolic syndrome
